Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
Assenagon Asset Management S.A. Has $16.11 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
What is HC Wainwright’s Estimate for SRPT FY2024 Earnings?
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
Lightning Round: Sell Viking Therapeutics, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...
Law9d
Litigators of the (Past) Week: Defending Against a $290M Claim and Scoring a $116M Win in Drug Patent Fight
Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...
Sarepta Therapeutics: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
BioSpace4d
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Nasdaq3d
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...